Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $152.24, for a total value of $654,936.48. Following the transaction, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at approximately $327,924.96. This trade represents a 66.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, August 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42.

Palvella Therapeutics Stock Down 2.4%

NASDAQ PVLA opened at $150.56 on Friday. Palvella Therapeutics, Inc. has a 12-month low of $56.22 and a 12-month high of $161.38. The company has a market capitalization of $2.17 billion, a PE ratio of -31.17 and a beta of -0.25. The firm’s 50 day moving average is $149.44 and its 200-day moving average is $132.90.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). As a group, sell-side analysts expect that Palvella Therapeutics, Inc. will post -6.36 EPS for the current year.

Wall Street Analysts Forecast Growth

PVLA has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $270.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Truist Financial set a $207.00 target price on Palvella Therapeutics in a research report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Chardan Capital upgraded Palvella Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a research report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Palvella Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $209.14.

Institutional Trading of Palvella Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Palvella Therapeutics during the 2nd quarter worth about $140,343,000. Summit Partners Public Asset Management LLC grew its stake in Palvella Therapeutics by 1,016.0% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock valued at $40,761,000 after buying an additional 354,525 shares during the last quarter. First Light Asset Management LLC raised its holdings in Palvella Therapeutics by 38.3% in the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock valued at $122,251,000 after acquiring an additional 271,617 shares during the period. Primecap Management Co. CA bought a new position in Palvella Therapeutics in the 2nd quarter valued at about $39,150,000. Finally, Jennison Associates LLC lifted its position in Palvella Therapeutics by 65.3% during the first quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock worth $79,852,000 after acquiring an additional 253,128 shares during the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare genetic and dermatologic diseases. The company uses its proprietary QTORIN platform to formulate and deliver medicines locally to affected tissues, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella’s lead program is QTORIN 3.9% rapamycin, an investigational topical gel being developed for microcystic lymphatic malformations, rare lesions caused by abnormalities in the lymphatic system.